Recent Pfizer Press Releases

  • 1/14/08 7:30 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that the U.S. Patent & Trademark Office has issued its first communication in the reexamination of the ‘893 basic patent for Lipitor, initially rejecting the patent’s claims. This initial action, which is how the Office raises its issues with the patentee, will now be followed by the company’s response, in which Pfizer will address those issues raised by the examiner. As themore...
  • 1/9/08 6:23 pm EST

    Decision Consistent With Similar Ruling in Federal Court in November 2007

    NEW YORK--(BUSINESS WIRE)--Pfizer Inc announced today that a New York state court ruled in favor of the company on an important motion relating to litigation over Pfizer’s Celebrex medication. New York Supreme Court Justice Shirley W. Kornreich ruled that the plaintiffs suing Pfizer in New York failed to present reliable scientific evidence necessary to prove that Celebrex can cause heart attacks and strokes at 200 mg daily – the mostmore...
  • 1/9/08 2:44 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 12 Noon EST on Wednesday, January 23. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s Fourth Quarter 2007 Performance Report, to be issued that morning. To view and listen to the webcast and view the Performance Report,more...
  • 1/8/08 12:25 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc today named Sally Susman Senior Vice President of Worldwide Communications and Chief Communications Officer with overall responsibility for Pfizer’s global communications, reporting to Chairman and Chief Executive Officer Jeff Kindler. She will join Pfizer’s Executive Leadership Team. Ms. Susman is a communications executive with wide experience in corporate communications, mediamore...
  • 1/8/08 7:00 am EST
    LOS ANGELES--(BUSINESS WIRE)--DoveBid, Inc., the leading global provider of capital asset auction and valuation services, announced today that it will conduct a series of biotech and pharmaceutical lab equipment sales via a featured online auction (FOA) for Pfizer Japan, Inc.’s laboratory located in Nagoya, Japan. Pfizer is a global leader in the development, production, marketing and sales of innovative healthcare products. Themore...
  • 1/7/08 1:00 am EST
    NEW YORK & TOKYO--(BUSINESS WIRE)--Pfizer Inc [Headquarter: New York, NY, USA, CEO: Jeffrey B. Kindler] (hereinafter, Pfizer) and Taisho Pharmaceutical Co., Ltd. [Headquarter: Toshima-ku, Tokyo, Japan, President: Akira Uehara] (hereinafter, Taisho) have signed a definitive agreement, which replaces the letter of intent previously signed between the companies, for worldwide (excluding Japan) collaboration to research, develop andmore...
  • 1/3/08 12:15 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc said today it will appeal a Canadian Federal Court decision in favor of generic manufacturer Apotex in its challenge to a Pfizer patent covering Lipitor. The court denied Pfizer’s request to prevent Apotex from launching a generic version of Lipitor prior to the expiration of Pfizer’s enantiomer (calcium salt) patent in July 2010. The court’s decision has no immediate commercialmore...
  • 1/3/08 7:14 am EST
    LONDON--(BUSINESS WIRE)--84 percent of ex-smokers who consulted with their doctor or another healthcare professional during their final successful quit attempt believe that giving up would have been more difficult if they had tried to quit alone – according to the results of a new European survey announced today.(1) The survey, which investigated the attitudes of nearly 1,000 ex-smokers on smoking and smoking cessation, revealed that 74 percentmore...
  • 12/31/07 8:00 am EST
    NEW YORK--(BUSINESS WIRE)--Pfizer (NYSE:PFE) announced today that it has completed the cash tender offer to purchase all of the outstanding shares of common stock of Coley Pharmaceutical Group, Inc. (Nasdaq:COLY). The tender offer expired, as scheduled, at midnight, Eastern time, on Friday, December 28, 2007. The offer was not extended. A total of 24,050,054 shares of Coley common stock were validly tendered and not withdrawn prior to themore...
  • 12/21/07 2:05 pm EST
    NEW YORK--(BUSINESS WIRE)--Pfizer Inc today announced that it has received an approvable letter from the U.S. Food and Drug Administration (FDA) issued for dalbavancin HCl, Pfizer’s once-weekly two-dose antibiotic under FDA review for the treatment of adult patients with complicated skin and skin structure infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The FDA recently published a draft guidancemore...